DNAprint Genomics (DNAG)

[worktoplay]

A little more on the Biofrontera IPO. Rough translation:

http://translate.google.com/translate?hl=en&sl=de&u=http://www.vwd.de/vwd/news.htm%3Fid%3D24...

FRANKFURT (Dow Jones) -- the Biofrontera AG, Leverkusen, wants to go in the first half-year 2006 into Frankfurt to the stock exchange. The Biotechunternehmen aims at a quotation at the regulated market, said enterprise spokeswoman Anke to mills on Monday. Which banks will be taken part in the stock exchange course and how large the block of shares will be, did not say to mills however.

Already in November 2005 Biofrontera on the German own capital funds forum had explained to want to go to the stock exchange. In August Biofrontera conversion loans of 20 millions EUR at the Frankfurt stock exchange had platziert.

1997 created enterprises has four medicines in praeklinischen and clinical phases and is specialized in dermatologische research. The first means against horn disturbances of the skin, atkinische Keratosen so mentioned, is to come 2008 on the market. After representation of the chairman of the board Hermann Luebbert the means has a turnover potential of more than 180 millions EUR. For a further medicine against Nesselsucht the permission is aimed at 2009 and a Umsatzpotenzial is seen from 200 millions to 400 millions EUR.

With the incomes from the stock exchange course Biofrontera wants its marketing to develop and into further projects in early clinical phases to invest.

Of Gangolf Schrimpf, Dow Jones Newswires,

[e-mail], +49 (0)69 - 29725 108,

DJG/DJN/ssu/rio


02.01.2006, 02.01.